Pulse Biosciences, Inc.

Equities

PLSE

US74587B1017

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX 10:33:33 2024-04-25 am EDT 5-day change 1st Jan Change
6.705 USD -2.26% Intraday chart for Pulse Biosciences, Inc. -8.63% -45.06%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Health Care Stocks Slide Late Afternoon MT
Pulse Biosciences Shares Fall After Q4 Results, Rights Issue Plans MT
Transcript : Pulse Biosciences, Inc., Q4 2023 Earnings Call, Mar 28, 2024
Pulse Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Pulse Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Sector Update: Health Care Stocks Ease Late Afternoon MT
Pulse Biosciences Gets FDA Clearance For Percutaneous Electrode System MT
Pulse Biosciences, Inc. Announces FDA 510(K) Clearance for its CellFX nsPFA Percutaneous Electrode System CI
Pulse Biosciences, Inc. Announces Positive 60-Day Follow-Up Evaluations for Initial Patients Treated in the Cellfx Nspfa 360° Cardiac Catheter First-In-Human Feasibility Study CI
Sector Update: Health Care Stocks Decline Pre-Bell Tuesday MT
Pulse Biosciences Files FDA Notification to Advance Testing of New Cardiac Clamp MT
Pulse Biosciences Files 510(K) Submission with U.S. FDA for its CellFX nsPFA Cardiac Clamp CI
Pulse Biosciences, Inc. Announces First-In-Human Procedures with its Novel CellFX Nanosecond Pulsed Field Ablation Cardiac Catheter CI
Pulse Biosciences Insider Bought Shares Worth $843,504, According to a Recent SEC Filing MT
Pulse Biosciences Insider Bought Shares Worth $1,117,085, According to a Recent SEC Filing MT
Pulse Biosciences Up 16% on Product Updates, Potential Stock Purchases by Duggan DJ
Pulse Biosciences Cleared to Start Catheter Ablation Feasibility Trial; Set to File Application for Cardiac Clamp; Shares Rise MT
Sector Update: Health Care Stocks Rise Tuesday Afternoon MT
Sector Update: Health Care MT
Pulse Biosciences Shares Climb On Application for Percutaneous Electrode Review DJ
Pulse Biosciences Files Premarket Notification to FDA for CellFX nsPFA Percutaneous Electrode MT
Pulse Biosciences, Inc. Announces Filing of Premarket Notification 510(k) to U.S. Food and Drug Administration for its Novel CellFX nsPFA Percutaneous Electrode CI
Pulse Biosciences Insider Bought Shares Worth $123,470, According to a Recent SEC Filing MT
Transcript : Pulse Biosciences, Inc., Q3 2023 Earnings Call, Nov 13, 2023
Pulse Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Chart Pulse Biosciences, Inc.
More charts
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Company’s Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.
Calendar
Related indices
More about the company
  1. Stock Market
  2. Equities
  3. PLSE Stock
  4. News Pulse Biosciences, Inc.
  5. Pulse Biosciences : Secures FDA Clearance for Nano-Pulse Stimulation Technology